Dexamethasone decreases membrane fluidity of leukemia cells

Area of Science:

• Cell Biology
• Biochemistry
• Oncology

Background:

• Leukemia cell membrane fluidity influences cellular processes.
• Dexamethasone is a glucocorticoid used in leukemia treatment.
• The role of membrane fluidity in dexamethasone's efficacy is not fully understood.

Purpose of the Study:

• To investigate the effect of dexamethasone on leukemia cell plasma membrane fluidity.
• To determine if this effect is mediated by glucocorticoid receptors.

Main Methods:

• Measuring steady-state fluorescence polarization (P) of 1,6-diphenyl-1,3,5-hexatriene.
• Treating primary leukemia cells and cell lines with dexamethasone in vitro.
• Comparing membrane fluidity in glucocorticoid-sensitive and resistant cells.

Main Results:

• Dexamethasone induced a dose-, time-, and temperature-dependent increase in membrane fluidity (P values).
• This effect was observed in primary leukemia cells and sensitive cell lines with glucocorticoid receptors.
• Glucocorticoid-resistant cells lacking specific dexamethasone binding showed no change in membrane fluidity.

Conclusions:

• Dexamethasone modulates leukemia cell membrane fluidity.
• The mechanism involves a classical glucocorticoid receptor-dependent pathway.
• This finding suggests a potential role for membrane fluidity modulation in dexamethasone therapy for leukemia.